1. Home
  2. BAFN vs CVM Comparison

BAFN vs CVM Comparison

Compare BAFN & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

HOLD

Current Price

$5.11

Market Cap

26.6M

Sector

Finance

ML Signal

HOLD

Logo Cel-Sci Corporation

CVM

Cel-Sci Corporation

HOLD

Current Price

$1.12

Market Cap

21.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
CVM
Founded
1999
1983
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6M
21.4M
IPO Year
2021
1996

Fundamental Metrics

Financial Performance
Metric
BAFN
CVM
Price
$5.11
$1.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
18.6K
450.6K
Earning Date
04-30-2026
05-13-2026
Dividend Yield
1.00%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$264,033.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
65.45
52 Week Low
$4.80
$0.89
52 Week High
$15.45
$13.48

Technical Indicators

Market Signals
Indicator
BAFN
CVM
Relative Strength Index (RSI) 29.47 28.57
Support Level $4.80 $0.89
Resistance Level $6.75 $1.59
Average True Range (ATR) 0.34 0.12
MACD -0.04 0.03
Stochastic Oscillator 1.96 15.98

Price Performance

Historical Comparison
BAFN
CVM

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About CVM Cel-Sci Corporation

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.

Share on Social Networks: